EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA‐EX‐01 Randomised, Double‐Blind, Placebo‐Controlled Trial

Bewegung und wöchentliches Sirolimus (Rapamycin) bei älteren Erwachsenen: randomisierte, doppelblinde, placebokontrollierte Studie RAPA-EX-01

Brad Stanfield iD, Brian Leroux, Matt Kaeberlein, Julie Jones, Ruth Lucas

Journal of Cachexia, Sarcopenia and Muscle · 2026-04 · 17 (2)

DOI: 10.1002/jcsm.70274 ↗

Auf einen Blick

In dieser explorativen Studie verbesserte Bewegung die Leistung in beiden Gruppen. Sirolimus 6 mg wöchentlich verstärkte die funktionellen Gewinne nicht; in Sensitivitätsanalysen fiel der Effekt zugunsten von Placebo aus.

Fragestellung

Erhöht oder hemmt einmal wöchentliches Sirolimus (Rapamycin) die funktionellen Effekte eines Heimtrainings bei älteren Erwachsenen?

Methode

Randomisierte, doppelblinde, placebokontrollierte Studie mit 40 sitzenden Erwachsenen im Alter von 65–85 Jahren; Sirolimus 6 mg oder Placebo 1:1 über 13 Wochen plus standardisiertes Heimtraining 3-mal/Woche.

Ergebnisse

Primärer ITT-Endpunkt: Differenz −2,13 Wiederholungen beim 30-s-Chair-Stand (95 %-KI −4,61 bis 0,34; p = 0,089). CC: −2,46 (95 %-KI −4,87 bis −0,06; p = 0,045); PP: −3,44 (95 %-KI −5,86 bis −0,99; p = 0,007).

Schlussfolgerung der Autor:innen

In dieser explorativen Studie verstärkte Sirolimus 6 mg wöchentlich die kurzfristigen funktionellen Verbesserungen durch das Heimtraining nicht und könnte sie in Sensitivitätsanalysen leicht abgeschwächt haben.

Kernaussagen

  • 30-s-Chair-Stand im ITT: −2,13 Wiederholungen mit Sirolimus gegenüber Placebo
  • CC und PP fielen zugunsten von Placebo aus
  • Mehr unerwünschte Ereignisse insgesamt unter Sirolimus (99 vs. 63)

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 15.04.2026. Verfasst von Brad Stanfield und 4 weiteren Autor:innen. Beteiligte Einrichtung: Royal New Zealand College of General Practitioners, Wellington, New Zealand. Hauptthemen laut MEDLINE: Sirolimus, Exercise. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dr Brad Stanfield Ltd.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preclinical models suggest alternating activation and inhibition of mechanistic target of rapamycin complex 1 (mTORC1) could enhance adaptation to exercise (‘cycling hypothesis’). Whether this concept translates to older adults is unknown. This exploratory trial assessed whether once‐weekly sirolimus (rapamycin) 6 mg enhances or inhibits functional gains from a home‐based exercise programme.

Methods

In this randomised, double‐blind, placebo‐controlled trial, 40 sedentary adults aged 65–85 years (mean 72.2 years; 47.5% female) were assigned (1:1) to sirolimus (rapamycin) 6 mg or matched placebo once weekly for 13 weeks. Both groups performed a standardised home‐based resistance (chair‐stands) and endurance (exercycle) programme three times/week. The primary outcome was the change in 30‐s chair‐stand repetitions at 13 weeks (intention‐to‐treat; ANCOVA adjusted for baseline performance, age stratum and sex). Complete‐case (CC) and per‐protocol (PP) analyses were prespecified sensitivity analyses. Secondary outcomes included grip strength, 6‐min walk distance, SF‐36 physical and mental component scores, C‐reactive protein and several epigenetic age measures. Safety was assessed through adverse‐event monitoring and laboratory tests.

Results

Both groups improved chair‐stand performance. The primary intention‐to‐treat analysis showed an adjusted mean difference (sirolimus–placebo) of −2.13 repetitions (95% CI −4.61 to 0.34; p = 0.089). Sensitivity analyses favoured placebo and reached statistical significance: complete‐case analysis (16 sirolimus, 19 placebo) showed a difference of −2.46 repetitions (95% CI −4.87 to −0.06; p = 0.045) and per‐protocol analysis (15 sirolimus, 16 placebo) showed −3.44 repetitions (95% CI −5.86 to −0.99; p = 0.007). Secondary functional outcomes also favoured placebo but were not statistically significant: the adjusted mean difference for 6MWD was −4.87 m (95% CI −28.97 to 19.71; p = 0.706) and for grip strength was −1.13 kg (95% CI −3.52 to 1.18; p = 0.344). SF‐36 scores showed small, non‐significant differences favouring placebo. Quality‐of‐life scores showed small, non‐significant differences favouring placebo. Seventeen participants (85%) in each arm reported ≥ 1 adverse event, but the total burden was higher with sirolimus (99 vs. 63 events), including one possibly drug‐related serious adverse event (pneumonia).

Conclusion

In this exploratory trial, once‐weekly sirolimus (rapamycin) 6 mg did not enhance, and in sensitivity analyses, it may have modestly attenuated short‐term functional improvements from a home exercise programme in older adults. The regimen also increased the burden of minor adverse events and may have contributed to one serious infection. Future trials with longer treatment duration or less frequent/lower dosing are needed to determine whether a favourable benefit–risk profile can be achieved. Trial Registration: ACTRN12624000790549

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusExerciseHumansAgedFemaleDouble-Blind MethodMaleAged, 80 and over

Stichwörter der Autor:innen

Geroscienceagingexercise trainingmTORmTORC1 inhibitionphysical functionrandomised controlled trialrapamycinsarcopeniasirolimus

Substanzen

Sirolimus

Autor:innen und Institutionen

  • Royal New Zealand College of General Practitioners, Wellington, New Zealand.
  • University of Auckland, Auckland, New Zealand.
  • University of Washington, Seattle, Washington, USA.
  • Optispan Inc., Seattle, Washington, USA.
  • BioValeo, Wellington, New Zealand.

ORCID-Profile: Brad Stanfield

Förderung

  • Dr Brad Stanfield Ltd

Zitieren

APA

Stanfield, B., Leroux, B., Kaeberlein, M., Jones, J., & Lucas, R. (2026). Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA‐EX‐01 Randomised, Double‐Blind, Placebo‐Controlled Trial. Journal of Cachexia, Sarcopenia and Muscle, 17(2). https://doi.org/10.1002/jcsm.70274

Vancouver

Stanfield B, Leroux B, Kaeberlein M, Jones J, Lucas R. Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA‐EX‐01 Randomised, Double‐Blind, Placebo‐Controlled Trial. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(2). doi:10.1002/jcsm.70274

BibTeX
@article{Stanfield2026,
  author = {Stanfield, Brad and Leroux, Brian and Kaeberlein, Matt and Jones, Julie and Lucas, Ruth},
  title = {Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA‐EX‐01 Randomised, Double‐Blind, Placebo‐Controlled Trial},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2026},
  volume = {17},
  number = {2},
  doi = {10.1002/jcsm.70274}
}
Kostenlos starten →